The purpose of this study was to identify molecular markers associated with tumor recurrence and survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in developed countries (1) . Patient survival depends on loco-regional control (50-90%) , and the presence of distant metastasis (10-25%) or secondary tumors (10-40%). Cure rates with surgery or radiotherapy (RT) are high (70-90%) when the disease is detected at early stages (2) . However, two-thirds of HNSCC patients have advanced tumor stages at diagnosis and this is associated with poor disease-free and overall survival (OS) (2) .
In the last years, chemotherapy combined with surgery or/and RT has shown benefit in organ preservation and loco-regional control in locally advanced patients (3) .
However, despite the success of these new combined strategies in organ preservation and quality-of-life improvement, 5-year survival rates have not markedly improved and remain at approximately 50% (1, 4) .
This may be due to the clinicopathological, molecular and genetic heterogeneity of HNSCCs. Tumors with similar histopathological appearance often respond differently to chemotherapy. Conventional TNM staging and histopathological tumor grade have prognostic value in HNSCC, but they are insufficient to guide the selection of therapy for individual patients (5, 6) . Currently, HPV infection and response to induction chemotherapy (IC) are the only useful features in predicting response in HNSCC (1, 7) . Patients with HPV-positive tumors treated with chemotherapy have a more favorable clinical outcome than patients with HPV-negative tumors. However, its utility as a predictive marker is limited to a specific subset of HNSCC located in the oropharynx. Evaluation of response to IC could only be performed after three cycles of genotoxic treatment, delaying and complicating the alternative surgical resection of the tumor in non-responder patients.
Molecular markers promise to have a significant clinical relevance, in terms of guiding treatment strategies, if they were able to predict response and to distinguish patients who could benefit from the genotoxic treatment. Many studies have used microarray technology to identify gene expression signatures associated with carcinogenesis or related to HNSCC clinical outcome (8) (9) (10) (11) (12) (13) (14) . Nevertheless, patients at different tumor stages are often pooled together in the same analysis, making it difficult to obtain results that could be translated to the clinical setting. We performed a prospective microarray study in locally advanced HNSCC patients, which were treated at our institution with concomitant chemoradiotherapy (CRT) or IC. We evaluated the expression profile of pre-treatment tumor biopsies and identified three distinct HNSCC subtypes that displayed different clinical outcome. In addition, we identified a subset of genes associated with tumor recurrence and patient survival. Finally, we validated the prognostic value of the tumor subtypes expression signature using HNSCC microarray data sets from two previously described studies.
Methods

Patient Characteristics and Treatment Plan
All patients included in our microarray study had a pathologically confirmed, untreated, locally advanced (stages III, IVA and IVB) HNSCC and were treated at Hospital de la Santa Creu i Sant Pau (HSCSP). Patients defined as not operable at diagnosis were treated with concomitant CRT (stage IVB), whereas operable patients (stage III or IVA) were treated with IC followed by CRT/RT or surgery.
IC consisted of the administration of cisplatin at a dose of 100 mg/m 2 on day 1, and 5-FU at a dose of 1000 mg/m 2 /day by continuous intravenous infusion on days 2 to 6 every 3 weeks, for three courses. Response was defined as a reduction in primary tumor volume, measured by physical examination, fiber-optic laryngoscopy and CT scan/MR imaging, following RECIST criteria. After IC, patients whose tumor showed a complete response or a partial response above 50% received conservative treatment (RT or CRT). Patients with stable or progressive disease after IC were treated with surgery, usually followed by RT. From 1995 to 2002, patients with a good tumor response to IC followed RT protocol. In 2003, CRT was introduced progressively and replaced RT as the treatment of choice after IC. RT, at a total dose of 70 Gy, was administered in 35 fractions of 2 Gy each, over a 7 week period. CRT consisted in RT at the same doses plus three cycles of cisplatin at a dose of 100mg/m 2 .
RNA Extraction
The study was performed using 63 fresh, pre-treatment, primary tumor biopsies and five normal mucosa samples obtained from HNSCC patients. A sample aliquot was used for pathological diagnosis of the malignancy and another aliquot was immersed in RNA later (Applied Biosystems Incorp, Foster City, CA), frozen in cold isopentane and kept in liquid nitrogen until RNA processing. All samples included in the microarray analysis had a minimum of 80% of tumor cells. Normal mucosa samples were obtained from areas without apparent clinical and histological alterations. Total RNA was extracted with Trizol (Invitrogen Ltd, Paisley, UK) as previously described (15) and cleaned using RNeasy® Spin columns (Qiagen Incorp, Valencia, CA). Total RNA was quantified spectrophotometrically. The Agilent 2100 Bioanalyzer and the RNA Nano 6000 kit (Agilent Technologies, Santa Clara, USA) were used to determine the integrity of total RNA. Only samples with an RNA integrity number higher than seven were included.
RNA labeling, hybridization and pre-processing of microarray data cDNA and cRNA synthesis, and microarray hybridization were performed using 2μg of total RNA from each sample as starting material and the GeneChip One-Cycle Target Labelling and Control Reagents Kit, following the instructions described in the Affymetrix user's manual. Biotinylated cRNA quality was checked using the Agilent 2100 Bioanalyzer. Ten micrograms of cRNA, previously fragmented, were hybridized to the Affymetrix HG-U133A 2.0 array (Affymetrix, Santa Clara, CA, USA) at 45ºC for 16 h. Probe washing and staining was performed in a Fluidics Station 450 applying the midi_ euk2v3_450 protocol. Microarrays were scanned using a Gene Chip Scanner 3000 (Affymetrix, Santa Clara, CA, USA). Microarray images were acquired using GCOS software (Affymetrix, Santa Clara, CA, USA). All subsequent data analyses were performed with '.CEL' files, which contained the intensity image information of each microarray experiment. All the microarray '.CEL' files included in the study were pre-processed applying the robust multi-array average algorithm implemented in the Bioconductor statistical affy package (http://www.bioconductor.org) (16) .
Unsupervised Analysis (cluster analysis)
We carried out a non-specific filtering by selecting probe sets with an expression level higher than log 2 (100) in at least 25% of the samples, with an interquartile range across samples larger than 0.5 and a median expression level greater than log 2 (300), as previously described (17) . After filtering, we used microarray data to perform a two-way complete-linkage hierarchical cluster analysis using the Euclidian distance cluster analysis, and cluster visualization were preformed with the 'MEV' software v4.0 (Dana Farber Cancer Institute).
We used Kaplan-Meier curves and two-tailed log-rank test to estimate differences in the adjusted local recurrence-free survival (LRFS), progression free-survival (PFS) and OS among tumor class (cluster). Univariate and multivariate Cox regression model analysis were applied to test the association between tumor cluster classification and other clinical variables (node involvement, tumor size and localization) with LRFS, PFS and OS. One patient was excluded from the analysis because he presented a distant metastasis at diagnosis and his treatment differed significantly from that used in locally advanced stages. LRFS was defined as the time from diagnosis to recurrence at the primary tumor location. PFS was defined as the time from diagnosis to recurrence at the primary site, lymph node or distant metastasis. OS was defined as the time from diagnosis to patient death as a consequence of cancer. All patients began treatment in 1-2 weeks after diagnosis. The median follow-up time was 2.5 years.
Supervised analysis
To identify genes that were differentially expressed in each cluster, we performed a supervised differential expression analysis using the Bioconductor limma package (18) . Each contrast was generated by comparing two of the tumor classes identified by cluster analysis. False discovery rate was applied for multiple testing correction. Supervised analysis was performed with all 22215 data sets present in the HG-U133A2.0 microarray. Probe sets with a false discovery rate value lower than 0.05 were identified as differentially expressed.
Gene Ontology and biological pathway analysis was performed with GOstats hypergeometric test (GOstats package) (19) . We identified relevant biological terms and pathways, described in the Gene Ontology and in the Kyoto Encyclopedia of Genes and Genomes databases, which were over-represented among the differentially expressed genes. We selected significant terms with a P value lower than 0.001. Receiver operating characteristic (ROC) analysis was used to identify genes associated with local tumor recurrence and patient death. We selected genes with the highest area under the curve in predicting local recurrence or patient death. In ROC analysis, we included patients with a minimum follow-up time of two years, also including those who suffered a primary tumor recurrence or died during these first two years.
Quantitative RT-PCR mRNA expression was measured on an ABIPRISM 7000 Sequence Detection System (Applied Biosystems Incorp, Foster City, CA), using pre-designed Taqman ® Gene Expression Primer and probe Assays for RAB25 (Hs00220628_ m1), DUOX1 (Hs00213694_m1), THBS1 (Hs00962914_m1), FHL2 (Hs00179935_m1), TGM3 (Hs00162752_m1) and HPRT1 (Hs99999909_m1) (Applied Biosystems Incorp, Foster City, CA) as previously described (15) . The HPRT1 gene was the endogenous control and the RNA obtained from the HNSCC UM-SCC-22A cell line (a gift from Dr. R. H Brakenhoff) was used as the calibration sample. The association of gene expression with LRFS, PFS and OS was assessed applying a Cox regression model analysis. Differences were considered significant at P values < 0.05 in all applied statistical tests. Statistical analyses were performed using the SPSS software v.14.01 (SPSS, Inc., Chicago, IL).
Gene Set Enrichment Analysis and cluster signature validation
We defined two prognostic (favorable/poor) gene signatures associated with patient survival using genes differentially expressed among tumor subtypes. The favorable prognosis signature consisted of overexpressed genes in subtype 3 tumors and underexpressed genes in subtype 1 and 2 tumors. Genes underexpressed in subtype 3, genes overexpressed in subtype 1 and genes overexpressed in subtype 2 tumors were included in the gene signature associated with poor prognosis.
We used Gene Set Enrichment Analysis (GSEA) to validate the association between the defined prognosis signatures and patient survival using two independent cohorts of HNSCC patients (20) . We used data sets and clinical information of two independent microarray studies, previously published, available in the Array Express (E-TABM-302) (13) and Gene Expresion Omnibus (GSE2837) (8) databases. GSEA ranked genes according with their association with the death sensor sample classification (alive/death) and computed an enrichment score for each prognostic signature. We selected genes significantly enriched in both GSEA studies to generate a new refined gene prognosis signature. Using the expression data matrix of this new prognosis signature, we computed an average expression score for each of the patients included in our study (HSCSP cohort), as previously described (21). To obtain the average expression score, we subtracted the mean expression of each gene, and then we calculated, for each patient, the mean expression of all the genes included in the prognosis signature. The power of the average expression score to predict patient survival was assessed applying a multivariate Cox regression model analysis. We classified patients in three groups depending on their average expression score to perform Kapplan-Meier curves analysis. High score group included patients with an average expression score higher than the mean for all samples. Low score group included patients with an average score lower than the mean minus the standard deviation. Intermediate score group included patients with a score lower than the high score group and higher than the low score group. Kaplan-Meier survival curves and log-rank test were performed to analyze the differences in OS among these three groups of patients. Average expression score analysis was replicated using data from the E-TABM-302 cohort.
Results
Hierarchical clustering (Class discovery)
Sixty-three pre-treatment HNSCC biopsies and five normal samples were analyzed using the Affymetrix HG-U133A2.0 array. Patient's characteristics are summarized in Table I . After normalization and non-specific filtering, we selected 814 probe sets for cluster analysis (Supplementary Figure 1) . Unsupervised hierarchical clustering identified three principal sample clusters according to their gene expression pattern ( Figure 1A ). Nineteen tumor biopsies were grouped in cluster 1 (Cl1) and 23 in cluster 2 (Cl2). Cluster 3 (Cl3) included 21 tumor biopsies. Normal mucosa samples were grouped in a subcluster within the Cl3.
Cluster classification was significantly associated with LRFS (P=0.001), PFS (P=0.009) and OS (P=0.004) (Figure 1 ). Patients with tumors in Cl2 and Cl3 had a higher LRFS than patients whose tumors were included in Cl1 (P<0.001) ( Figure 1B , upper right plot). Cl3 patients had a higher PFS (P=0.04) and OS (P=0.003) than patients from Cl1 and Cl2 (Figure 1B medium and bottom right plots, respectively).
Multivariate Cox model analysis showed that tumor cluster classification was an independent risk factor for LRFS (P<0.001), PFS (P=0.02) and OS (P<0.01) (Table II) . Cl1 patients had an increased risk of primary tumor recurrence as compared with patients with tumors in Cl2 or Cl3. Cl3 patients had a lower risk of suffering a disease recurrence or death than Cl1 or Cl2 patients. Tumor size, localization and node involvement were not significantly associated with LRFS, PFS or OS.
We obtained similar results for LRFS, PFS and OS when we included in the analysis only patients who followed a genotoxic treatment (CRT or IC plus CRT/RT). A multivariate Cox model analysis showed that tumor cluster classification was significantly associated with LRFS (P=0.02), PFS (P=0.05) and OS (P<0.01), identifying this classification as an independent risk factor in patients treated with genotoxic therapy (Table II) . In contrast, we did not observe significant differences when the Cox analysis was performed with patients treated with surgery after IC (Table II) .
Treatment modality (concomitant CRT or IC), tumor size, node involvement and age were not associated with cluster classification (Supplementary Table I ). Only tumor location reached a near to significant association with cluster classification because the Cl2 subtype lack oral cavity tumors.
Differential expression analysis and biological characteristics of tumor subtypes
A total of 269 probe ( Figure 1C ), common to Cl1-Cl2 (Supplementary  Table II) and Cl1-Cl3 (Supplementary Table III) comparisons, were selected as differentially expressed in subtype 1 tumors (Supplementary Table V) . Similarly, we selected 121 probe sets ( Figure 1C ), common to Cl1-Cl2 and Cl2-Cl3 (Supplementary Table  III) comparisons, as differentially expressed in subtype 2 tumors (Supplementary Table V) . Finally, 176 probe sets were common to the Cl1-Cl3 and Cl2-Cl3 comparisons ( Figure 1C ) and were identified as differentially expressed in subtype 3 tumors (Supplementary Table  V) . FHL2 and TGM3 genes were common to all comparisons (FHL2, Cl1>Cl3>Cl2; TGM3, Cl3>Cl2>Cl1). These results were confirmed by qPCR (Supplementary Figure 2) .
Genes overexpressed in subtype 1 were involved in cell adhesion, NF-kappaB pathway and integrin signaling (Table III) , and coded for components of the extracellular region and basement membrane (Supplementary Table VI) . On the other hand, genes underexpressed Gene expression signatures and molecular markers in Cl1 tumors were involved in keratinocyte differentiation and metabolism of xenobiotics by cytocrome P450 (Supplementary Table VI) . Genes overexpressed in Cl2 tumors participated in development and branching morphogenesis (Table III) . Genes overexpressed in subtype 3 tumors were involved in epidermis morphogenesis and keratinocyte differentiation (Table III) . These genes coded for components of the extracellular region and the cornified envelope (Supplementary  Table VIII) . Moreover, a large number of genes overexpressed in subtype 3 tumors were located in chromosome regions 1q21 and 19q13 (Supplementary Figure 3) . Histological tumor grade was not associated with tumor subtype classification (P=0.307). However, most poorly differentiated tumors were classified into subtypes 1 and 2 (Supplementary Table IX) .
Genes associated with local tumor recurrence and patient death
We identified a subset of genes with a high accuracy to predict local tumor recurrence and patient death by ROC analysis (Table IV) . The subset of genes with the highest sensitivity and specificity in predicting tumor recurrence and/or patient survival were involved in cell adhesion, cell communication, extracellular matrix regulation, protein transport and keratinocyte differentiation.
As an internal control, we tested the reliability of the expression data obtained in the microarrays analysis, measuring by RT-PCR the expression levels of three of these genes (RAB25, THBS1 and DUOX1) in 50 tumor samples included in the microarray study. Cox model analysis showed that RAB25 and DUOX1 mRNA expression levels were associated with LRFS (P=0.01; P= 0.04), PFS (P<0.01; Genes which expression levels were inversely associated with tumor recurrence or patient death
Gene expression signatures and molecular markers Table X ). THBS1 mRNA expression levels were associated with PFS (P<0.01) and OS (P<0.01) (Supplementary Table X) . Patients whose tumors expressed high RAB25 or DUOX1 mRNA levels had a higher LRFS and OS than patients bearing tumors expressing low levels. Patients with tumors showing high THBS1 expression had a higher risk of death than patients bearing low THBS1 expressing tumors.
Validation of the cluster gene signature associated with patient survival in two independent cohorts and prognostic signature refinement We used the genes differentially expressed among tumor subtypes (HSCSP cohort) to design two prognostic (favorable or poor) gene expression signatures associated with patient survival (see Supplementary Figure 5 and methods). We applied GSEA to validate the association between these two cluster signatures and patient survival in two independent HNSCC data sets previously published by Rickman et al. (E-TABM.302) and Chung et al. (GSE2837) (8,13) . GSEA showed that 106 genes of the favorable prognosis signature were enriched in patients who remained alive at the end of follow-up of E-TABM-302 study (Figure 2A, right plot) . Similarly, when we performed the analysis with data from the GSE2837 study (Figure 2A , left plot), we identified 107 genes of the favorable prognosis signature enriched in patients who remained alive. These results validated the association of these genes of the cluster signature with patient survival. We did not observe significant differences associated with the poor prognosis signature (data not shown).
Once we independently confirmed our cluster gene signature, we wanted to refine it by diminishing the number of genes included in the prognosis signature. To this aim, we selected the subset of genes enriched in both GSEA studies (E-TABM-302 and GSE2837). We generate a 50-gene favorable prognosis signature (Supplementary  Table XI) . We calculated an average expression score (See methods) of all the genes included in the refined signature for each of the tumor specimens included in our study (HSCSP cohort) . Cox model analysis showed that the expression of the 50-gene signature was an independent risk factor associated with patient survival (P<0.001) (Supplementary Table XII) . By applying Kaplan-Meier survival curves, we observed that patients with a high expression of the favorable prognosis signature had a lower risk of death than patients with an intermediate or low expression ( Figure 2B, left plot) . We confirmed these results by classifying Rickman's study samples Gene expression signatures and molecular markers (E-TABM-302) using the 50-gene signature. Again, patients with a high expression of the 50-gene signature had a lower risk of death than patients with an intermediate or low expression ( Figure 2B , right plot and Supplementary Table XII) .
Discussion
We used cluster analysis to identify three HNSCC subtypes that are significantly associated with LRFS, PFS and OS. Most of the patients with subtype 1 tumors suffered a tumor recurrence within 2 years after treatment, resulting in a decrease in their OS. In contrast, patients bearing subtype 3 tumors had a low risk of local recurrence and a high probability of surviving after treatment. These patients obtained the greatest clinical benefit from the genotoxic treatment. Subtype 2 patients had a high local disease control but some of them died as a result of regional lymph nodes or distant metastases, supporting the idea that subtype 2 tumors initially respond to genotoxic treatment but their predisposition to metastasize may reduce patient survival. Tumor subtype classification remained an independent risk factor for tumor recurrence and patient survival when we excluded from the analysis patients who received surgery after IC. This suggests that tumor subtype classification, in addition to being a prognostic factor, was associated with the effectiveness of the genotoxic treatment.
Molecular differences among tumor subtypes associated with aggressiveness, metastatic propensity and/or resistance to genotoxic could explain their diversity in patient clinical outcome. Subtype 1 tumors, which are the group with the poorest outcome, showed activation of biological processes related to invasiveness, motility and tumor progression. These tumors overexpressed SERPINE1, LGALS1, PLAU and several integrins, whose expression increases tumor cell migration and invasiveness (22) (23) (24) (25) . Moreover, subtype 1 tumors overexpressed genes involved in the epithelial-mesenchymal transition (EMT) (ITGB1, THBS1, SERPINE1, LGALS1, LOXL2, PLOD2, P4HA1, P4HA2, INBHA, WISP1, FN1, MET and HMGA2) and in NF-κB activation (Table III) . Alterations in these pathways have been associated with increased invasiveness, metastatic capacity and resistance to apoptosis (4, (26) (27) (28) (29) (30) (31) . In addition, these tumors overexpressed genes of the TGFβ and TNFα pathways, which also participate in the induction of EMT (26, 32) . Moreover, subtype 1 tumors underexpressed genes involved in xenobiotic metabolism, suggesting that they may have a reduced capacity to detoxify alcohol and tobacco carcinogens, agents known to predispose to HNSCC. These tumors underexpressed also genes involved in keratinocyte differentiation and epidermis morphogenesis. Therefore, the poor prognosis of subtype 1 tumors could be explained by their EMT-like phenotype, their enhanced capacity to invade and metastasize, their resistance to apoptosis and their poor degree of differentiation.
The biological features of subtype 3 tumors support the notion that this subtype displays the highest degree of differentiation and the lowest ability to generate loco-regional or distant metastases. These tumors overexpressed genes involved in epidermis morphogenesis, which products localize to cell structures characteristic of differentiated keratinocytes (33, 34) . A considerable number or these genes were clustered in chromosome regions 1q21 and 19q13, indicating a propensity for these loci to undergo alterations in HNSCC. Other groups have reported the involvement of genes located in the 1q21 region in terminal differentiation of the human epidermis (35, 36) . On the other hand, genes mapping to the 19q13 region are mainly underexpressed in the transition from invasive to metastatic HNSCC (37) . The genomic alteration in this chromosomal region involves loss of heterozygosity in primary HNSCC tumors and correlates with metastasis in regional lymph nodes and tumor aggressiveness (38) . Moreover, genes of the kallikrein protein family, which play a role in extracelular matrix remodeling and tumor progression, are located within the 19q13 region (39) .
Genes overexpressed in subtype 2 tumors were implicated in the development of the tubular epithelium and protein oligomerization, and showed a differentiation pattern intermediate between subtype 1 and subtype 3 tumors. These findings suggest that branching morphogenesis may be involved in the metastatic progression of this tumor subtype, in a similar manner to what has been suggested for tubular-type (luminal) breast cancer (40) . Further analyses will be necessary to clarify the biological characteristics responsible for the clinical outcome of this intermediate tumor subtype.
Using ROC analysis, we selected the subset of genes associated, with the highest sensitivity and specificity, with LRFS and OS. As an internal control, we analyzed the gene expression levels of three of these genes (RAB25, DUOX1 and THBS1) by qRT-PCR, and obtained the same results as in microarray analysis. In agreement with our findings, RAB25 expression, which is involved in membrane trafficking and vesicular transport, is absent in the poor prognosis triple negative breast tumors and promotes the development of intestinal neoplasia in mice (41, 42) . Studies in breast, ovarian and colon tumors suggest that RAB25 may act as, either, a tumor suppressor or as an oncogene, depending on the tumor subtype (41) (42) (43) . DUOX1, which is involved in host defense and promotion of wound healing, is underexpressed in primary non-small cell lung cancer and derived cell lines (44) . In turn, THBS1 is involved in platelet aggregation, angiogenesis and tumorigenesis. Its overexpression confers poor prognosis in hepatocellular carcinomas (45) , whereas in non-small cell lung cancer is a good prognostic marker (46) . These genes could be good candidates for predicting the effectiveness of the genotoxic therapy in HNSCC; however, an independent prospective study in patients treated with chemotherapy and RT would be necessary to validate their ability.
Most importantly, we used GSEA analysis and two independent microarray data sets of surgical patients, published by Chung et al. (8) and Rickman et al.(13) , to validate the cluster gene signature obtained in our series. GSEA results showed that a subset of genes of favorable prognosis, included in the cluster signature, were overexpressed in patients remained alive at the end of these two independent studies.
Patients bearing tumors with a higher expression of these genes have a lower risk of death than patients with a lower expression. This suggests that the downregulation of these genes could have a dominant role in the acquisition of a more invasive and metastatic tumor phenotype. A similar pattern of downregulation was observed in a HNSCC microrray study focused on the identification of a gene signature associated with lymph node metastasis (9) . Recently, whole genome sequencing studies also identified mutations in genes that regulate squamous development and differentiation (47, 48) .
It is relevant to underscore that Chung's and Rickman's studies included mainly surgical patients. In comparison with these series, our study was conducted specifically in patients with locally advanced tumors following a genotoxic protocol and identified a gene expression signature associated with local recurrence and patient survival. Chung's and Rickman's studies have allowed us to validate the prognostic value of our gene signature. However, besides prognosis, we believe that our signature could also predict the effectiveness of the genotoxic therapy.
The most straight forward application of this gene expression signature would be to identify patients who would benefit from genotoxic treatment using pre-treatment tumor biopsies. They would have the lower risk of tumor recurrence and death, and their treatment of choice would be concomitant CRT. Thus, in these patients, IC could be spared and treatment speeded. In addition, the identification of responder patients before treatment could decrease the number of unnecessary radical surgery procedures, thereby increasing rates of organ preservation and patient quality of life. A second use of this expression signature would be to avoid unnecessary treatment of patients bearing tumors with intrinsic resistance to genotoxic therapy who would have a poor clinical outcome.
However, independent prospective studies would be necessary to assess if the proposed survival signature, in addition to its prognostic value, could predict the efficacy of the genotoxic treatment. Its validation as a predictive signature will help in guiding HNSCC therapy selection, in a similar way to what has been done in locally advanced breast cancer, in which a signature with a strong prognostic value is able to predict chemotherapy efficacy (49, 50) .
